secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0000950170-23-031624
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta appoints Alyssa Levin as CFO and Business Officer effective July 1
-------------------------------------------------------------------------

- Annual base salary of $450k, sign-on bonus of $20k, and a stock option for 442,400 shares.
- Option vests 25% on July 1, 2024, then monthly over 36 months; exercise price = June 30 closing.
- Levin previously CFO at ViaCyte (acquired by Vertex), Tentarix, and Bird Rock Bio.
- Target annual incentive bonus set at 40% of base salary.
- Company is developing engineered NK cell therapies for cancer (NKX101, NKX019).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023031624/0000950170-23-031624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023031624/nktx-20230629.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-031624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer